GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » ROIC %

Viva Biotech Holdings (HKSE:01873) ROIC % : 3.34% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Viva Biotech Holdings's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was 3.34%.

As of today (2024-06-06), Viva Biotech Holdings's WACC % is 8.87%. Viva Biotech Holdings's ROIC % is 6.00% (calculated using TTM income statement data). Viva Biotech Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Viva Biotech Holdings ROIC % Historical Data

The historical data trend for Viva Biotech Holdings's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings ROIC % Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial 6.56 4.36 3.99 4.50 6.29

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.58 5.13 5.06 1.41 3.34

Competitive Comparison of Viva Biotech Holdings's ROIC %

For the Biotechnology subindustry, Viva Biotech Holdings's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viva Biotech Holdings's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's ROIC % distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's ROIC % falls into.



Viva Biotech Holdings ROIC % Calculation

Viva Biotech Holdings's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=280.144 * ( 1 - -78.35% )/( (8889.358 + 7009.661)/ 2 )
=499.636824/7949.5095
=6.29 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8845.335 - 775.367 - ( 757.768 - max(0, 2984.484 - 2165.094+757.768))
=8889.358

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8148.556 - 595.572 - ( 1133.507 - max(0, 1678.052 - 2221.375+1133.507))
=7009.661

Viva Biotech Holdings's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=219.55 * ( 1 - -22.38% )/( (9096.15 + 7009.661)/ 2 )
=268.68529/8052.9055
=3.34 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8911.628 - 889.571 - ( 1174.297 - max(0, 3448.957 - 2374.864+1174.297))
=9096.15

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8148.556 - 595.572 - ( 1133.507 - max(0, 1678.052 - 2221.375+1133.507))
=7009.661

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viva Biotech Holdings  (HKSE:01873) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Viva Biotech Holdings's WACC % is 8.87%. Viva Biotech Holdings's ROIC % is 6.00% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Viva Biotech Holdings ROIC % Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Viva Biotech Holdings (HKSE:01873) Business Description

Traded in Other Exchanges
Address
735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation ("CDMO") and commercialisation services segment includes contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations.
Executives
Mao Chen Cheney 2101 Beneficial owner
Wu John Jiong 2201 Interest of corporation controlled by you
Fenghe Harvest Ltd 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Mao Jun 2501 Other
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Zhou Min 2202 Interest of your spouse
Intertrust (singapore) Ltd. 2301 Trustee
Z&m International Holdings Limited 2201 Interest of corporation controlled by you
Zhang And Sons Limited 2101 Beneficial owner

Viva Biotech Holdings (HKSE:01873) Headlines

No Headlines